Repatha

Phase 3Small molecule

UUniversity of California, Los Angeles

Repatha is one of 5 small molecule programs targeting STEMI. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

STEMIActive, not recruiting

STEMIPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in STEMI

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Repatha

UUniversity of California, Los Angeles

Phase 3

1 3

Calciparine

BBaxter Healthcare Corporation

Preclinical

1 4

Unfractionated Heparin

GSK

Preclinical

1 5

Β -Blockers

QQilu Hospital of Shandong University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis1 trial

Reducing Intracranial atheroSclErosis With Repatha

Terminated·UUniversity of California, Los Angeles·Phase 4·NCT04573777·10 enrolled

STEMI1 trial

Evolocumab in STEMI

Active, not recruiting·SSejong General Hospital·Phase 3·NCT06081803·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Repatha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Repatha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Repatha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, Los Angeles

Repatha

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atherosclerosis1 trial

STEMI1 trial

References

Drug Info

Quick Facts

Related News